BRAF and therapy-related myeloid neoplasm: Unlike t-MN patients with CHIP most commonly involving TP53 and PPM1D, a variety of genes were observed in the patients with lymphoid tissue malignancies: DNMT3A, a DNA methyltransferase; EXH2 and KMT2D, which are involved in histone modification; CREBBP, which is involved in the p53-dependent signal pathways; KRAS and BRAF, with roles in the RAS/MAPK pathway; and STAT3, which plays a role in cell proliferation.